Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Monopar Therapeutics (MNPR)

Annual Return

Over the past 3 years, MNPR has had an average annual return of +130.52%, outperforming the benchmark SPY, which returned +22.45% annual.

Over the past 5 years, MNPR has had an average annual return of +15.50%, outperforming the benchmark SPY, which returned +13.88% annual.

Since Dec 19, 2019, MNPR has had an average annual return of -11.41%, underperforming the benchmark SPY, which returned +15.84% annual.

20262025202420232022202120202019
-7.24%+196.87%+1,196.88%-85.68%-26.18%-47.55%-63.14%-37.36%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-7.53%-9.24%-0.02%-4.81%+24.72%-6.89%-7.24%
2025+99.76%-20.08%+3.70%+14.85%-24.11%+12.73%+15.11%-17.08%+139.19%+5.50%+0.02%-24.23%+196.87%
2024-0.78%+146.46%-17.89%-3.11%-7.23%+19.48%-4.35%-31.82%+182.78%+116.11%+54.55%-2.35%+1,196.87%
2023+51.12%-12.58%-55.55%-19.05%-13.18%-12.47%-13.31%-12.86%-4.10%-30.77%-32.72%+17.43%-85.68%
2022-8.09%+4.76%-17.50%-10.60%-6.05%+7.43%-14.75%-8.24%-15.46%+61.67%+4.53%-7.84%-26.18%
2021+38.11%-13.61%-15.06%-3.08%-4.98%+3.16%-9.85%-2.64%-5.79%-1.47%-8.28%-27.09%-47.55%
2020-13.55%-33.09%-25.37%+2.70%+4.65%-3.13%-1.60%-23.03%-5.25%-17.08%+9.97%+25.35%-63.14%
2019-37.36%-37.36%

Drawdown analysis of Monopar Therapeutics (MNPR)

The maximum drawdown for the MNPR was -98.93%, occurring on Nov 20, 2023. This drawdown has not yet recovered.

The current MNPR drawdown is -55.14%.

Since Dec 19, 2019 MNPR has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 1 time
DepthStartTo BottomBottomTo RecoverEndTotal
-98.93%Dec 20, 2019985Nov 20, 2023OngoingOngoingOngoing